A randomized, open-label, adaptive, proof-of-concept clinical trial of modulation of host thromboinflammatory response in patients with COVID-19: the DAWn-Antico study.
Trials. 2020 Dec 9;21(1):1005. doi: 10.1186/s13063-020-04878-y.
Trials. 2020.
PMID: 33298149
Free PMC article.
Clinical Trial.